SanBio Co (JP:4592) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
SanBio Co. has completed its second commercial production run of AKUUGO suspension for intracranial implantation, achieving expected yield results. The company anticipates starting shipments by the second quarter of the fiscal year ending January 2026, pending compliance with specification tests. This development is expected to have minimal impact on the current fiscal year’s financial performance.
For further insights into JP:4592 stock, check out TipRanks’ Stock Analysis page.
